Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-681323 dose response in active RA
NCT00134693Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2005
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of dilmapimod in rheumatoid arthritis (RA), sponsored by GSK. Started Jun 2005; status: completed.
02
Drugs
dilmapimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00134693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134693.